Data from RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer
Anthony Howell(Breast Cancer Care), D. Gareth Evans(Manchester Academic Health Science Centre), Jamie C. Sergeant(Manchester Academic Health Science Centre), Jack Cuzick(Queen Mary University of London), Linda Ashcroft(The Christie NHS Foundation Trust), Jamie Motion, Mitch Dowsett(Institute of Cancer Research), Lesley Fallowfield(Brighton and Sussex Medical School), Adam R. Brentnall(Queen Mary University of London), Ann Ward(University of York), Judith E. Adams(German Cancer Research Center), Rosemary Greenhalgh(Cancer Research UK Manchester Institute), Caroline Boggis, Rosalind A. Eeles(Royal Marsden NHS Foundation Trust)
Cited by 0
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k